Adaptive Biotech officer plans $29.6K stock sale

A company officer at Adaptive Biotechnologies has filed a Rule 144 notice to sell 1,195 shares of ADPT common stock tied to previously granted RSUs.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp (ADPT) received a Rule 144 notice from officer Susan Bobulsky covering a planned sale of 1,195 shares of common stock through Morgan Stanley Smith Barney LLC. The shares relate to Restricted Stock Units granted on March 4, 2024, and the issuer’s common stock trades on NASDAQ.

The notice also lists prior sales under a Rule 10b5-1 trading plan over the past three months, including multiple transactions in June, July, and August 2026, each disclosing shares sold and aggregate dollar proceeds.

Key Figures

Shares to be sold under Rule 144: 1,195 shares Aggregate market value of planned sale: $29,612.10 Shares outstanding reference: 159,595,842 shares +5 more

8 metrics

Shares to be sold under Rule 144 1,195 shares Planned sale of Adaptive Biotechnologies common stock reported for Susan Bobulsky

Aggregate market value of planned sale $29,612.10 Value associated with the 1,195 ADPT shares covered by the Rule 144 notice

Shares outstanding reference 159,595,842 shares Common stock share count referenced in the securities information section

10b5-1 sale on August 10, 2026 3,000 shares; $75,000.00 ADPT common stock sold under a 10b5-1 plan for Susan Bobulsky

10b5-1 sale on July 30, 2026 1,299 shares; $31,176.00 ADPT common stock sold under a 10b5-1 plan for Susan Bobulsky

10b5-1 sale on July 16, 2026 5,000 shares; $115,000.00 ADPT common stock sold under a 10b5-1 plan for Susan Bobulsky

10b5-1 sale on July 1, 2026 487 shares; $10,714.00 ADPT common stock sold under a 10b5-1 plan for Susan Bobulsky

10b5-1 sale on June 25, 2026 5,000 shares; $102,500.00 ADPT common stock sold under a 10b5-1 plan for Susan Bobulsky

Key Terms

Rule 144, Restricted Stock Units, 10b5-1 Sales, common stock, +1 more

5 terms

Rule 144 regulatory

"This is a LIVE Form 144 notice of proposed sale of securities"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Common | 03/04/2024 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Sales regulatory

"10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

common stock financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

NASDAQ market

"| 09/15/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ADPT disclose about Susan Bobulsky?

It discloses that officer Susan Bobulsky has filed a Rule 144 notice to sell 1,195 shares of Adaptive Biotechnologies common stock, originally acquired through Restricted Stock Units granted on March 4, 2024, with sales to be handled by Morgan Stanley Smith Barney LLC.

How many ADPT shares are covered by the new Rule 144 sale notice?

The notice covers 1,195 shares of Adaptive Biotechnologies common stock. The filing lists an aggregate market value of $29,612.10 for these shares in connection with the planned Rule 144 sale.

What prior ADPT stock sales by Susan Bobulsky are reported in the last three months?

The filing reports several Rule 10b5-1 sales of ADPT common stock: 5,000 shares on June 25, 2026; 487 shares on July 1, 2026; 5,000 shares on July 16, 2026; 1,299 shares on July 30, 2026; and 3,000 shares on August 10, 2026, each with stated dollar proceeds.

How many Adaptive Biotechnologies shares are outstanding as referenced in the filing?

The Form 144 references 159,595,842 shares of Adaptive Biotechnologies common stock, which is listed in the securities information section alongside the planned sale details.

What type of equity award is associated with the ADPT shares being sold?

The shares being sold are linked to Restricted Stock Units granted on March 4, 2024. The filing identifies the security type for the planned sale as common stock derived from these RSUs issued by Adaptive Biotechnologies.

Is the planned ADPT stock sale under a 10b5-1 trading plan?

The filing labels prior three-month transactions as 10b5-1 Sales, but the securities-to-be-sold section for the 1,195 shares does not itself state that this particular planned sale is under a 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:36 PM Accepted by SEC EDGAR 09/15/2026 - 04:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001820885
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ADAPTIVE BIOTECHNOLOGIES CORPORATION
SEC File Number	001-38957
Address of Issuer	1165 Eastlake Avenue East Seattle WASHINGTON 98109
Phone	2066590067
Name of Person for Whose Account the Securities are To Be Sold	SUSAN BOBULSKY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1195	29612.10	159595842	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/04/2024	Restricted Stock Units	Issuer			1195	03/04/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA 98109	Common	08/10/2026	3000	75000.00
10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA 98109	Common	07/30/2026	1299	31176.00
10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA 98109	Common	07/16/2026	5000	115000.00
10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA 98109	Common	07/01/2026	487	10714.00
10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA 98109	Common	06/25/2026	5000	102500.00

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/16/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Susan Bobulsky
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)